Substantially improved objective response, PFS, and OS irrespective of BRAF status have propelled the nivo + ipi combination as a standard of care in melanoma, despite increases in grade 3–4 adverse events in patients treated with the combination (3, 31, 32). This evidence concerns the gene BRAF and melanoma.